Prequalification status issued for Shantha's pentavalent vaccine

HONG KONG – Four years after it was sidelined, a pentavalent vaccine produced by the Indian arm of Sanofi Pasteur (the vaccine division of Sanofi SA) – Shantha Biotechnics Ltd. – received prequalification status from the World Health Organization. The prequalification means that United Nations agencies like UNICEF can now purchase the vaccine for use across its programs, mostly in emerging countries.

To continue reading subscribe now to BioWorld Asia (formerly International)